



ciberonc

Centro de Investigación Biomédica en Red
Cáncer

II CIBERONC GENERAL MEETING

1 YEAR

>650 members

>240 articles

>10 meetings

February 2nd 2018

Real Academia Nacional de Medicina

C/ Arrieta, 12. Madrid



REAL ACADEMIA NACIONAL
DE MEDICINA DE ESPAÑA



ciberonc
Centro de Investigación Biomédica en Red
Cáncer



MINISTERIO
DE ECONOMÍA, INDUSTRIA
Y COMPETITIVIDAD

ic

Instituto
de Salud
Carlos III



FONDO EUROPEO DE
DESARROLLO REGIONAL
Una manera de hacer Europa
FONDO SOCIAL EUROPEO
El FSE invierte en tu futuro

9:30 Registrations

10:00 Welcome

Jesús Fernández Crespo. Director of ISCIII

Joaquín Arribas. Scientific Director of CIBERONC

Eduardo Díaz-Rubio. Vice-president of RANM

10:30 Gastro-Intestinal Tumors Program

Chair: **Gabriel Capellá.** IDIBELL. Coordinator of GI Program

Integrating genomic and transcriptomic markers of response to targeted therapies in advanced CRC to clinical practice. **Rodrigo Dientsmann.** VHIO

Unraveling etiologic pathways leading to pancreatic cancer (YLR talk) **Esther Molina.** CNIO

11:15 Breast Cancer Program

Chair: **Joan Albanell.** IMIM. Co-coordinator of BC Program

Resistance to trastuzumab-emtansine. **Atanasio Pandiella.** CIC. Coordinator of BC Program

A novel immunonanotherapy targeting Gasdermin-B reduces tumor progression in breast cancer (YLR talk). **Gema Moreno.** UAM

12:00 Coffee Break/Posters Session

12:30 Respiratory Tract Tumors Program

Chair: **Luis Montuenga.** CIMA. Coordinator of RTT Program

Activation of the complement system in lung cancer: Exploring new diagnostic markers and immunotherapy approaches. **Rubén Pio.** CIMA

N-Cadherin is responsible for FGFR1/4 oncogenicity and predictive of anti-FGFR therapy efficacy (YLR talk). **Irene Ferrer.** H.12 Octubre/ CNIO

13:15 Hematological Tumors Program

Chair: **Dolors Colomer.** IDIBAPS. Coordinator of HT Program

Discovery of novel epigenetic inhibitors for treatment of hematological malignancies. **Felipe Prosper.** Clínica Universidad de Navarra

Unraveling the complex landscape of genetic alterations in mantle cell lymphoma (YLR talk). **Sílvia Beà.** IDIBAPS

14:00 Lunch / Posters Session

15:00 Low Prevalence Tumors Program

Chair: **Enrique de Álava**. IBiS Coordinator of LPT Program

The potential of nanotechnology to provide novel diagnostic and therapeutic alternatives for low prevalence tumours. **María de la Fuente**. ONCOMET

2020: Finding an active treatment for metastatic uveal melanoma patients (YLR talk). **Josep María Piulats**. IDIBELL

15:45 Mechanism of Tumor Progression Program

Chair: **Xosé Bustelo**. CIC. Coordinator of MTP Program

Time- and Tissue-dependent metastasis mechanisms. **Roger Gomis**. IRB

A new tumor suppressor mechanism in T cell acute lymphoblastic leukemia (YLR talk). **Javier Robles Valero**. CIC

16:30 Break

16:45 Training and Mobility Program

Chair: **Amparo Cano**. UAM. Coordinator of T&M Program

Mitochondrial morphological and functional reprogramming following CD137(4-1BB) co-stimulation (abstracts competition winner in post-doctoral modality). **Álvaro Tejeira**. CIMA

p95HER2-T Cell Bispecific Antibody for Breast Cancer Treatment (abstracts competition winner in pre-doctoral modality). **Irene Rius**. VHIO

17:30 Closing and Awards

 @CIBERONC #IGMCIberonc

POSTERS INDEX

- BC1** Exploring the molecular mechanisms of resistance to MEK inhibition in pancreatic cancer
- BC2** Unanticipated therapeutic combinations in cancer: therapy-induced senescence and antibody-drug conjugates (ADCs)
- GIT1** Primary constitutional MLH1 epimutations: A focal epigenetic event
- GIT2** Germline RNF43 mutations are a rare cause of serrated polyposis
- GIT3** A role for endothelial nitric oxide synthase in intestinal stem cell proliferation and mesenchymal colorectal cancer
- GIT4** Germline CNV detection in genetic diagnostics: benchmark of algorithms for CNV calling from NGS data at single exon resolution
- GIT5** Highly sensitive MLH1 methylation analysis in blood allows the identification of low-level epigenetic mosaicism
- GIT6** Standardization of the in vitro mismatch repair assay used in the functional characterization of mismatch repair variants
- GIT7** Gata4: understanding the balance between inflammation and tumor initiation in pancreatic cancer
- GIT8** MTH1 and OGG1 in familial colorectal cancer and polyposis
- HT1** A New Molecular Assay Identifies Conventional and Leukemic Non-Nodal Mantle Cell Lymphoma Molecular Subtypes
- HT2** A Novel Single Next-Generation Sequencing Approach for the Molecular Karyotyping and Genotyping of Patients with Myelodysplastic Syndromes and Related Neoplasms
- HT3** Association of miRNA expression profiles with functional and molecular Acute Myeloid Leukemia categories
- HT4** Next Generation Sequencing techniques identify cryptic insertions of immunoglobulin gene regulatory regions near CCND1 and CCND3 in mantle cell lymphoma
- HT5** In vitro and in vivo models of Acute Myeloid Leukemia using CRISPR/Cas9 system
- HT6** Research of preexisting mutations in hematopoietic stem cells in patients with therapy-related myeloid neoplasms by Deep Sequencing
- HT7** Clinical application of next generation sequencing on Acute Myeloid Leukemia
- HT8** Analysis of synonymous variants identified by Deep Sequencing in patients with de novo Acute Myeloid Leukemia (AML)
- HT9** Targeting TLR Signaling in Chronic Lymphocytic Leukemia with a Selective IRAK-4 Inhibitor
- LPT1** Hypoxia-mediated translational activation of ITGB3 in breast cancer cells enhances TGF- β signalling and malignant features in vitro and in vivo
- LPT2** Prognostic value of vitronectin presence in neuroblastoma
- RTT1** Stemness characterization of tumor spheres from non-small cell lung cancer. Differential expression in CSC-related markers and signaling pathways
- RTT2** Establishment of an immunoregulatory gene score as an independent prognostic biomarker in resectable non-small cell lung cancer adenocarcinoma
- RTT3** Characterisation of immune microenvironment in cancer stem cells in non-small cell lung cancer. Analysis of immunosuppressive and immunoregulatory factors
- MTP1** Targeting Squamous Cell Carcinoma through the Exchange Factor Vav2
- MTP2** Implications of Sos1 in mitochondrial oxidative stress
- MTP3** Lung adenocarcinoma and sarcomatoid carcinoma mouse model